JPM upgrades LRMR
JPMorgan initiates coverage of Larimar Therapeutics with an Overweight rating, citing potential growth prospects. This may impact the stock's performance.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.